Prevention and management of duodenal polyps in familial adenomatous polyposis

Gut

Volumn 54, Issue 7, 2005, Pages 1034-1043

  Brosens, L A A ^a,b   Keller, J J ^a,b   Offerhaus, G J A ^a,b   Goggins, M ^b   Giardiello, F M ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; APC PROTEIN; BETA CATENIN; CALCIUM; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERGOCALCIFEROL; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; K RAS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RANITIDINE; ROFECOXIB; SMAD4 PROTEIN; SULINDAC; SULINDAC SULFONE; URSODEOXYCHOLIC ACID;

ADENOMATOUS POLYP; ARGON LASER; ARGON PLASMA COAGULATION; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DUODENUM CANCER; DUODENUM POLYP; ENDOSCOPIC SURGERY; ENDOSCOPY; EPIDEMIOLOGICAL DATA; FAMILIAL ADENOMATOUS POLYP; FAMILIAL POLYPOSIS; GENE MUTATION; GENOTYPE; HUMAN; NONHUMAN; PANCREATICODUODENECTOMY; PHENOTYPE; PHOTODYNAMIC THERAPY; POLYPECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RNA INTERFERENCE; TREATMENT INDICATION; TUMOR LOCALIZATION; TUMOR RECURRENCE;

ADENOMATOUS POLYPOSIS COLI; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; DUODENAL NEOPLASMS; DUODENOSCOPY; HUMANS;

EID: 21044444991     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.053843     Document Type: Review

References (93)

1. Trimbath JD, Giardiello FM. Review article: genetic testing and counseling for hereditary colorectal cancer. Aliment Pharmacol Ther 2002;16:1843-57.
2. Tonelli F, Nardi F, Bechi P, et al. Extracolonic polyps in familial polyposis coli and Gardner's syndrome. Dis Colon Rectum 1985;28:664-8.
3. Sarre RG, Frost AG, Jogelman DG, et al. Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps. Gut 1987;28:306-14.
4. Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004;53:381-6.
5. Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 1999;31:412-16.
6. Galle TS, Juel K, Bulow S. Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 1999;34:808-12.
7. Pauli RM, Pauli ME, Hall JG. Gardner syndrome and periampullary malignancy. Am J Med Genet 1980;6:205-19.
8. Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992;102:1980-2.
9. Lillemoe K, Imbembo AL. Malignant neoplasms of the duodenum. Surg Gynecol Obstet 1980;150:822-6.
10. Vasen HF, Bulow S, Myrhoj T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997;40:716-19.
11. Bjork J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 2001;121:1127-35.
12. Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989;2:783-5.
13. Mahmoud NN, Dannenberg AJ, Bilinski RT, et al. Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. Carcinogenesis 1999;20:299-303.
14. Park JG, Park KJ, Ahn YO, et al. Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum 1992;35:996-8.
15. Iwama T, Mishima Y, Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 1993;217:101-8.
16. Iida M, Aoyagi K, Fujimura Y, et al. Nonpolypoid adenomas of the duodenum in patients with familial adenomatous polyposis (Gardner's syndrome). Gastrointest Endosc 1996;44:305-8.
17. Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001;48:515-21.
18. Bertario L, Russo A, Sala P, et al. Hereditary colorectal tumor registry. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003;21:1698-707.
19. Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998;62:1290-301.
20. Saurin JC, Ligneau B, Ponchon T, et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc 2002;55:342-7.
21. Groves C, Lamlum H, Crabtree M, et al. Mutation cluster region, association between germ-line and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol 2002;160:2055-61.
22. Attard TM, Cuffari C, Tajouri T, et al. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 2004;99:681-6.
23. Matsumoto T, Iida M, Kobori Y, et al. Progressive duodenal adenomatosis in a familial adenomatous polyposis pedigree with APC mutation at codon 1556. Dis Colon Rectum 2002;45:229-33.
24. Leggett BA, Young JP, Biden K, et al. Severe upper gastrointestinal polyposis associated with sparse colonic polyposis in a familial adenomatous polyposis family with an APC mutation at codon 1520. Gut 1997;41:518-21.
25. Trimbath JD, Griffin C, Romans K, et al. Attenuated familial adenomatous polyposis presenting as ampullary adenocarcinoma. Gut 2003;52:903-4.
26. Enomoto M, Konishi M, Iwama T, et al. The relationship between frequencies of extracolonic manifestations and the position of APC germ-line mutation in patients with familial adenomatous polyposis. Jpn J Clin Oncol 2000;30:82-8.
27. Matsumoto T, Lida M, Kobori Y, et al. Genetic predisposition to clinical manifestations in familial adenomatous polyposis with special reference to duodenal lesions. Am J Gastroenterol 2002;97:180-5.
28. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001;1:55-67.
29. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
30. Khan KN, Masferrer JL, Woerner BM, et al. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 2001;36:865-9.
31. Spigelman AD, Talbot IC, Penna C, et al. Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis. The Leeds Castle Polyposis Group (Upper Gastrointestinal Committee). J Clin Pathol 1994;47:709-10.
32. Nakatsubo N, Kashiwagi H, Okumura M, et al. Malignant change in a duodenal adenoma in familial adenomatous polyposis: report of a case. Am J Gastroenterol 1998;93:1566-8.
33. Kashiwagi H, Kanazawa K, Koizumi M, et al. Development of duodenal cancer in a patient with familial adenomatous polyposis. J Gastroenterol 2000;35:856-60.
34. Kashiwagi H, Spigelman AD, Talbot IC, et al. Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Br J Surg 1996;83:225-8.
35. Kashiwagi H, Spigelman AD, Talbot IC, et al. p53 and K-ras status in duodenal adenomas in familial adenomatous polyposis. Br J Surg 1997;84:826-9.
36. Takaku K, Oshima M, Miyoshi H, et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92:645-56.
37. Resnick MB, Gallinger S, Wang HH, et al. Growth factor expression and proliferation kinetics in periampullary neoplasms in familial adenomatous polyposis. Cancer 1995;76:187-94.
38. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96.
39. Saukkonen K, Rintahaka J, Sivula A, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003;111:915-25.
40. Groves CJ, Saunders BP, Spiqelman AD, et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002;50:636-41.
41. Saurin JC, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004;22:493-8.
42. Burke CA, Beck GJ, Church JM, et al. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999;49(3 Pt 1):358-64.
43. Moozar KL, Madlensky L, Berk T, et al. Slow progression of periampullary neoplasia in familial adenomatous polypasis. J Gastrointest Surg 2002;6:831-7.
44. Morpurgo E, Vitale GC, Galandiuk S, et al. Clinical characteristics of familial adenomatous polyposis and management of duodenal adenomas. J Gastrointest Surg 2004;8:559-64.
45. www.nccn.org/professionals/physician_gls/PDF/colorectal_screening.pd (accessed 15 April 2005).
46. Alarcon FJ, Burke CA, Church JM, et al. Familial adenomatous polyposis: efficacy of endoscopic and surgical treatment for advanced duodenal adenomas. Dis Colon Rectum 1999;42:1533-6.
47. Wahab PJ, Mulder G, den Hartog G, et al. Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy 1997;29:176-81.
48. Regula J, MacRobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX-a pilot study. Gut 1995;36:67-75.
49. Mlkvy P, Messmann H, Debinski H, et al. Photodynamic therapy for polyps in familial adenomatous polyposis-a pilot study. Eur J Cancer 1995;31A:1160-5.
50. Loh CS, Bliss P, Bown SG, et al. Photodynamic therapy for villous adenomas of the colon and rectum. Endoscopy 1994;26:243-6.
51. Abulafi AM, Allardice JT, Williams NS, et al. Photodynamic therapy for malignant tumors of the ampulla of Vater. Gut 1995;36:853-6.
52. Soravia C, Berk T, Haber G, et al. Management of advanced duodenal polyposis in familial adenomatous polyposis. J Gastrointest Surg 1997;1:474-8.
53. Bertoni G, Sassatelli R, Nigrisoli E, et al. Endoscopic snare papillectomy in patients with familial adenomatous polyposis and ampullary adenoma. Endoscopy 1997;29:685-8.
54. Norton ID, Geller A, Petersen BT, et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001;96:101-6.
55. Norton ID, Gostout CJ, Baron TH, et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002;56:239-43.
56. Penna C, Phillips RK, Tiret E, et al. Surgical polypectomy of duodenal adenomas in familial adenomatous polyposis: experience of two European centres. Br J Surg 1993;80:1027-9.
57. Penna C, Bataille N, Balladur P, et al. Surgical treatment of severe duodenal polyposis in familial adenomatous polyposis. Br J Surg 1998;85:665-8.
58. de Vos tot Nederveen Cappel WH, Jarvinen HJ, Bjork J, et al. Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polypasis. Br J Surg 2003;90:705-10.
59. Ruo L, Coit DG, Brennan MF, et al. Long-term follow-up of patients with familial adenomatous polyposis undergoing pancreaticoduodenal surgery. J Gastrointest Surg 2002;6:671-5.
60. Farnell MB, Sakorafas GH, Sarr MG, et al. Villous tumors of the duodenum: reappraisal of local vs. extended resection. J Gastrointest Surg 2000;4:13-21.
61. Chung RS, Church JM, van Stolk R. Pancreas-sparing duodenectomy: indications, surgical technique and results. Surgery 1995;117:254-9.
62. Kalady MF, Clary BM, Tyler DS, et al. Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg 2002;6:82-7.
63. Balladur P, Penna C, Tiret E, et al. Panctreatico-duodenectomy for cancer and precancer in familial adenomatous polyposis. Int J Colorectal Dis 1993;8(3):151-3.
64. Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-19.
65. Debinski HS, Trojan J, Nugent KP, et al. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995;345:855-6.
66. Seow-Choen F, Vijayan V, Keng V. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surg 1996;83:1763-6.
67. Richard CS, Berk T, Bapat BV, et al. Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis 1997;12:14-18.
68. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60.
69. Winde G, Schmid KW, Brandt B, et al. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997;40:1156-68.
70. Maclean AR, McLeod RS, Berk T, et al. A randomized trial comparing ursodeoxycholic acid and refecoxib, a selective COX-2 inhibitor, in the treatment of advanced duodenal adenomas in patients with familial adenomatous polyposis. Abstract. Gastroenterology 2001;120(suppl 1):A-254.
71. Parker AL, Kadakia SC, Maccini DM, et al. Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol 1993;88:93-4.
72. Theodore C. Adenomas of the ampulla of vater in familial adenomatous polyposis: Christian Theodore responds. Gastroenterology 2004;126:628-9.
73. Waddell WR, Ganser GF, Cerise EJ, et al. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
74. Wallace MH, Forbes A, Beveridge IG, et al. Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis. Dis Colon Rectum 2001;44:1585-9.
75. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8.
76. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
77. Seno H, Oshima M, Ishikawa TO, et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 2002;62:506-11.
78. Chapple KS, Scott N, Guillou PJ, et al. Interstitial cell cyclooxygenase-2 expression is associated with increased angiagenesis in human sporadic colorectal adenomas. J Pathol 2002;198:435-41.
79. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
80. Sato N, Maehara N, Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 2004;64:6950-6.
81. Zhang X, Morham SG, Langenbach R, et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-59.
82. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
83. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-42.
84. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000;36:664-74.
85. Koh TJ, Bulitta G, Fleming JV, et al. Gastrin is a target of the beta-catenin/ TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 2000;106:533-9.
86. Huang Y, He Q, Hillman MJ, et al. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 2001;61:6918-24.
87. Baek SJ, Kim KS, Nixon JB, et al. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-8.
88. Weyant MJ, Carothers AM, Bertagnolli ME, et al. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin Cancer Res 2000;6:949-56.
89. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-12.
90. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997;94:4312-17.
91. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 2000;97:13275-80.
92. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator- activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10.
93. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997;94:4318-23.